Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Liraglutide and semaglutide industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 Route of administration trends
2.1.5 Application trends
2.1.6 Distribution channel trends
Chapter 3 Liraglutide and Semaglutide Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of type 2 diabetes
3.2.1.2 Increasing obese population in developed nations
3.2.1.3 Increasing R&D investments to enhance clinical efficacy
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse side effects associated with use of liraglutide and semaglutide
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By route of administration
3.3.3 By application
3.3.4 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.6 Application potential
3.7 Pipeline analysis
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Liraglutide and Semaglutide Market Size and Forecast, By Type (USD Million)
5.1 Key trends, by type
5.2 Pills
5.3 Liquid
5.4 Drugs
Chapter 6 Liraglutide and Semaglutide Market Size and Forecast, By Route of Administration (USD Million)
6.1 Key trends, by route of administration
6.2 Parenteral
6.3 Oral
Chapter 7 Liraglutide and Semaglutide Market Size and Forecast, By Application (USD Million)
7.1 Key trends, by application
7.2 Type 2 diabetes mellitus
7.3 Obesity
7.4 Others
Chapter 8 Liraglutide and Semaglutide Market Size and Forecast, By Distribution Channel (USD Million)
8.1 Key trends, by distribution channel
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
Chapter 9 Liraglutide and Semaglutide Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of MEA
Chapter 10 Company Profiles
10.1 Novo Nordisk A/S
10.2 HEC Pharma Co
10.3 Viruj Pharmaceutical
10.4 Shenzhen JYMed Technology Co. Ltd.
10.5 Bachem Holding AG
10.6 Hangzhou Longshine Bio-Tech Co.,LTD
10.7 ALP Pharm Beijing Co., Ltd.
10.8 Hybio Pharmaceutical Co., Ltd.
10.9 Iris Biotech GMBH
10.10 Sun Pharmaceutical Industries Ltd.
